← Leaderboards
Xiaowu Pang
Tengen Biomedical Co.
$4,923,148
Attributed
$5,249,148
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–23$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,050,428 · 7
By mechanism
R42$3,000,000 · 1
R41$1,249,060 · 2
P20$1,224,608 · 3
R43$576,760 · 1
Top collaborators
- Yanfei Zhou3 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseUniversitiesAreaResearch PersonnelProgramsUnited States National Institutes Of HealthFunding OpportunitiesFundingStudentsMentorsCollaborationsPilot ProjectsCancer Research ProjectCancer Health DisparityMinority-Serving InstitutionResearch Project GrantsHuman PapillomavirusLeadMetropolitanApplications GrantsFlavivirusAnticancer ResearchHealth DisparityMalignant Neoplasms
Grant awards (21)
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2023 · AI · contact PI
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate$298,530
R41 · FY2023 · AI · contact PI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2022 · AI · contact PI
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate$298,530
R41 · FY2022 · AI · contact PI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)$1,000,000
R42 · FY2021 · AI · contact PI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$52,000
R41 · FY2021 · AI · contact PI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$300,000
R41 · FY2018 · AI · contact PI
Development of Zika viral pseudoinfectious virus as Zika vaccine candidate$300,000
R41 · FY2017 · AI · contact PI
1/2 Howard/Hopkins Intercenter Collaboration in HPV-Associated Cancer Studies$183,470
P20 · FY2017 · CA · contact PI
Project 1, Combination Immunotherapy for HPV-Associated Cancer$56,089
P20 · FY2017 · CA · contact PI
Administration Core$15,949
P20 · FY2017 · CA · contact PI
1/2 Howard/Hopkins Intercenter Collaboration in HPV-Associated Cancer Studies$220,295
P20 · FY2016 · CA · contact PI
Project 1, Combination Immunotherapy for HPV-Associated Cancer$66,688
P20 · FY2016 · CA · contact PI
Administration Core$19,234
P20 · FY2016 · CA · contact PI
1/2 Howard/Hopkins Intercenter Collaboration in HPV-Associated Cancer Studies$216,911
P20 · FY2015 · CA · contact PI
Project 1, Combination Immunotherapy for HPV-Associated Cancer$65,470
P20 · FY2015 · CA · contact PI
Administration Core$19,294
P20 · FY2015 · CA · contact PI
Administration Core$180,604
P20 · FY2014 · CA · contact PI
1/2 Howard/Hopkins Intercenter Collaboration in HPV-Associated Cancer Studies$180,604
P20 · FY2014 · CA · contact PI
Development of Pseudoinfectious VLP as Novel JEV Vaccine$284,464
R43 · FY2007 · AI · contact PI
Development of Pseudoinfectious VLP as Novel JEV Vaccine$292,296
R43 · FY2006 · AI · contact PI